Abstract
The peptides Api88 and Onc72 are highly efficient to treat Escherichia coli bacteremia in mice. Here we extended the animal studies to a systemic murine infection model using a multidrug-resistant carbapenemase-producing Klebsiella pneumoniae clinical isolate. When administered intraperitoneally three times at 2.5, 5 and 10 mg/kg bodyweight to CD-1 mice infected with a KPC-producing K. pneumoniae strain, both Api88 and Onc72 reduced the bacterial counts by at least 5 log10 units, indicating that both peptides are active in vivo. Both peptide treatments increased significantly the survival rates and average survival times compared to untreated animals for all doses except for the highest dose of Onc72. This dose reduced the bacterial counts so fast that it most likely induced a sudden release of large amounts of toxic materials from the killed bacteria reducing the survival time even below that of untreated mice. In conclusion, both peptides were efficient in the lethal murine K. pneumoniae infection model, but the treatment protocol (i.e. dose and time points) has to be further optimized based on future pharmacokinetic studies.
Keywords: Antibacterial peptides, Api88, Klebsiella pneumoniae carbapenemase (KPC), murine infection model, Onc72.
Protein & Peptide Letters
Title:In Vivo Activity of Optimized Apidaecin and Oncocin Peptides Against a Multiresistant, KPC-Producing Klebsiella pneumoniae Strain
Volume: 21 Issue: 4
Author(s): Eszter Ostorhazi, Eva Nemes-Nikodem, Daniel Knappe and Ralf Hoffmann
Affiliation:
Keywords: Antibacterial peptides, Api88, Klebsiella pneumoniae carbapenemase (KPC), murine infection model, Onc72.
Abstract: The peptides Api88 and Onc72 are highly efficient to treat Escherichia coli bacteremia in mice. Here we extended the animal studies to a systemic murine infection model using a multidrug-resistant carbapenemase-producing Klebsiella pneumoniae clinical isolate. When administered intraperitoneally three times at 2.5, 5 and 10 mg/kg bodyweight to CD-1 mice infected with a KPC-producing K. pneumoniae strain, both Api88 and Onc72 reduced the bacterial counts by at least 5 log10 units, indicating that both peptides are active in vivo. Both peptide treatments increased significantly the survival rates and average survival times compared to untreated animals for all doses except for the highest dose of Onc72. This dose reduced the bacterial counts so fast that it most likely induced a sudden release of large amounts of toxic materials from the killed bacteria reducing the survival time even below that of untreated mice. In conclusion, both peptides were efficient in the lethal murine K. pneumoniae infection model, but the treatment protocol (i.e. dose and time points) has to be further optimized based on future pharmacokinetic studies.
Export Options
About this article
Cite this article as:
Ostorhazi Eszter, Nemes-Nikodem Eva, Knappe Daniel and Hoffmann Ralf, In Vivo Activity of Optimized Apidaecin and Oncocin Peptides Against a Multiresistant, KPC-Producing Klebsiella pneumoniae Strain, Protein & Peptide Letters 2014; 21 (4) . https://dx.doi.org/10.2174/09298665113206660107
DOI https://dx.doi.org/10.2174/09298665113206660107 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Adjunctive Therapies for the Treatment of Tuberculosis
Current Molecular Medicine Identification of Antifungal Agents Using Combinatorial Approach: An Overview$
Current Medicinal Chemistry - Anti-Infective Agents Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy Abeta Immunotherapy and Other Means to Remove Amyloid
Current Drug Targets - CNS & Neurological Disorders Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Current Medicinal Chemistry Repurposing Ruxolitinib in Combating COVID-19: A Mini-review
New Emirates Medical Journal C-Met Inhibitors are Potential Novel Therapeutic Agents Against Listeria monocytogenes Infection Through Blocking the Bacteria Entry into Nonphagocytic Cells
Current Topics in Medicinal Chemistry Overview of Pediatric Epilepsy
Current Pediatric Reviews The Expanding Universe of γ δ T Lymphocytes: Subsets, Generation and Function
Current Immunology Reviews (Discontinued) Clinical Presentation of Autoinflammatory Syndromes in Childhood
Current Rheumatology Reviews Topical Delivery of Drugs for the Effective Treatment of Fungal Infections of Skin
Current Pharmaceutical Design Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry Multiple Myeloma or Brucellosis: A Case Report
Infectious Disorders - Drug Targets Delirium in Older Patients – A Review
Current Psychiatry Reviews TargetingQuorum Sensing and Competence Stimulation for Antimicrobial Chemotherapy
Current Drug Targets Natural Compounds Therapeutic Features in Brain Disorders by Experimental, Bioinformatics and Cheminformatics Methods
Current Medicinal Chemistry Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design New Insights into the Immune Response to Pneumococci
Current Respiratory Medicine Reviews Clinical Presentation, Treatment Outcome and Survival Among the HIV Infected Children with Culture Confirmed Tuberculosis
Current HIV Research